Anti-NBEA/ BCL8B/ LYST2 monoclonal antibody
Anti-NBEA/ BCL8B/ LYST2 antibody for FACS & in-vivo assay
Go to NBEA/NBEA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP0864-Ab-1/ GM-Tg-hg-MP0864-Ab-2 | Anti-Human NBEA monoclonal antibody | Human |
GM-Tg-rg-MP0864-Ab-1/ GM-Tg-rg-MP0864-Ab-2 | Anti-Rat NBEA monoclonal antibody | Rat |
GM-Tg-mg-MP0864-Ab-1/ GM-Tg-mg-MP0864-Ab-2 | Anti-Mouse NBEA monoclonal antibody | Mouse |
GM-Tg-cynog-MP0864-Ab-1/ GM-Tg-cynog-MP0864-Ab-2 | Anti-Cynomolgus/ Rhesus macaque NBEA monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP0864-Ab-1/ GM-Tg-felg-MP0864-Ab-2 | Anti-Feline NBEA monoclonal antibody | Feline |
GM-Tg-cang-MP0864-Ab-1/ GM-Tg-cang-MP0864-Ab-2 | Anti-Canine NBEA monoclonal antibody | Canine |
GM-Tg-bovg-MP0864-Ab-1/ GM-Tg-bovg-MP0864-Ab-2 | Anti-Bovine NBEA monoclonal antibody | Bovine |
GM-Tg-equg-MP0864-Ab-1/ GM-Tg-equg-MP0864-Ab-2 | Anti-Equine NBEA monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP0864-Ab-1/ GM-Tg-hg-MP0864-Ab-2; GM-Tg-rg-MP0864-Ab-1/ GM-Tg-rg-MP0864-Ab-2; GM-Tg-mg-MP0864-Ab-1/ GM-Tg-mg-MP0864-Ab-2; GM-Tg-cynog-MP0864-Ab-1/ GM-Tg-cynog-MP0864-Ab-2; GM-Tg-felg-MP0864-Ab-1/ GM-Tg-felg-MP0864-Ab-2; GM-Tg-cang-MP0864-Ab-1/ GM-Tg-cang-MP0864-Ab-2; GM-Tg-bovg-MP0864-Ab-1/ GM-Tg-bovg-MP0864-Ab-2; GM-Tg-equg-MP0864-Ab-1/ GM-Tg-equg-MP0864-Ab-2 |
Products Name | Anti-NBEA monoclonal antibody |
Format | mab |
Target Name | NBEA |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-NBEA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species NBEA/ BCL8B/ LYST2 VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-MP0864 |
Target Name | NBEA |
Gene ID | 26960,26422,361948,714386,477305,101088046,525624,100065416 |
Gene Symbol and Synonyms | BCL8B,LYST2,mKIAA1544,NBEA,NEDEGE,RGD1562629 |
Uniprot Accession | Q8NFP9 |
Uniprot Entry Name | NBEA_HUMAN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000172915 |
Target Classification | N/A |
The target: NBEA, gene name: NBEA, also named as BCL8B, LYST2. This gene encodes a member of a large, diverse group of A-kinase anchor proteins that target the activity of protein kinase A to specific subcellular sites by binding to its type II regulatory subunits. Brain-specific expression and coat protein-like membrane recruitment of a highly similar protein in mouse suggest an involvement in neuronal post-Golgi membrane traffic. Mutations in this gene may be associated with a form of autism. This gene and its expression are frequently disrupted in patients with multiple myeloma. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants may exist, but their full-length nature has not been determined.[provided by RefSeq, Feb 2011].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.